Teva stock plunged Wednesday — sacrificing an earlier breakout — despite beating Wall Street's third-quarter expectations and raising its guidance.Please watch the video at Investors.com - How Novo ...

Wednesday, Teva revealed booming third-quarter sales for its generics and biosimilars. In the U.S., revenue from the knockoffs came in at $1.1 billion, which was a 30% increase year over year, or ...

Teva gets a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. Their drug pipeline is robust and diverse, as well as existing ...